Compare
ArriVent BioPharma, Inc. vs Amylyx Pharmaceuticals, Inc. vs Rocket Pharmaceuticals, Inc. vs Keros Therapeutics, Inc.
| Latest fiscal year | ArriVent BioPharma, Inc. AVBP | Amylyx Pharmaceuticals, Inc. AMLX | Rocket Pharmaceuticals, Inc. RCKT | Keros Therapeutics, Inc. KROS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $0 | $244.06M |
| Revenue growth (YoY) | n/a | -100.0% | n/a | n/m |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | 27.7% |
| Net margin | n/a | n/a | n/a | 35.7% |
| Net income | -$166.31M | -$144.74M | -$223.12M | $87.01M |
| EPS (Diluted) | -$4.32 | -$1.53 | -$2.01 | $2.30 |
| Operating cash flow | -$160.59M | -$123.34M | -$190.01M | $107.50M |
| Free cash flow | n/a | -$123.48M | -$190.45M | $105.95M |
| Cash & equivalents | $45.54M | $226.65M | $77.56M | $287.42M |
| Total assets | $333.17M | $332.64M | $330.45M | $338.02M |
| Total liabilities | $25.95M | $27.39M | $53.23M | $34.89M |
| Shareholders' equity | $307.22M | $305.26M | $277.22M | $303.13M |
| Return on year-end equity | -54.1% | -47.4% | -80.5% | 28.7% |
| Shares outstanding | 42.45M | 109.88M | 108.32M | 19.54M |
Revenue, most recent five fiscal years
| Fiscal year | ArriVent BioPharma, Inc. | Amylyx Pharmaceuticals, Inc. | Rocket Pharmaceuticals, Inc. | Keros Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $0 Ended 2025-12-31 | $244.06M Ended 2025-12-31 |
| 1 year earlier | n/a | $87.37M Ended 2024-12-31 | $0 Ended 2024-12-31 | $3.55M Ended 2024-12-31 |
| 2 years earlier | n/a | $380.79M Ended 2023-12-31 | $0 Ended 2023-12-31 | $151.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $22.23M Ended 2022-12-31 | $0 Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | $285.0K Ended 2021-12-31 | $0 Ended 2021-12-31 | $20.10M Ended 2021-12-31 |